US FDA approves Alimtaas first-line regimen for mesothelioma

Published: 2004-02-27 06:56:00

Updated: 2004-02-27 06:56:00

Eli Lilly and Company said recently that the US Food and Drug Administration approved Alimta (pemetrexed), a first-line therapy developed by Eli Lilly designed to treat people with pleural mesothelioma. The FDA allows Alimta to be used for ineligible-for-surgery patients with diseases like mesoth...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK